Candel Therapeutics Financials - Benzinga

Candel Therapeutics Inc

CADLNASDAQ

Trade with Public

Trade with Public

$13.52

0.665.13%

Últ. Act.: Aug 25, 3:36 PM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Candel Therapeutics Financials

Candel Therapeutics (CADL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.23) by 126.09 percent. This is a 477.78 percent decrease over losses of $(0.09) per

Benzinga Newsdesk

PRO
Candel Therapeutics Q1 EPS $(0.14) Beats $(0.34) Estimate

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.34) by 58.82 percent. This is a 207.69 percent decrease over earnings of $0.13 per share

Benzinga Newsdesk

PRO
Candel Therapeutics Q4 EPS $(0.54) Misses $(0.24) Estimate

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.24) by 120.41 percent. This is a 35 percent decrease over losses of $(0.40) per share

Benzinga Newsdesk

Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED)

(Editor's note: The future prices of benchmark tracking ETFs, the lede, and the headline were updated in the story. Figures from economic reports were added.) U.S. stock futures declined on Friday following the release of key economic data. Futures of all the major benchmark indices ticked lower.

Rishabh Mishra

PRO
Candel Therapeutics Q2 EPS $(0.09) Beats $(0.17) Estimate

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.17) by 46.43 percent. This is a 87.84 percent increase over losses of $(0.74) per share

Benzinga Newsdesk

PRO
Candel Therapeutics Q1 EPS $0.13 Beats $(0.21) Estimate

Candel Therapeutics (NASDAQ:CADL) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $(0.21) by 161.9 percent. This is a 146.43 percent increase over losses of $(0.28) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved